Zura Bio (NASDAQ:ZURA) Receives Buy Rating from Guggenheim

Zura Bio (NASDAQ:ZURA - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Guggenheim in a note issued to investors on Wednesday,Benzinga reports. They presently have a $15.00 target price on the stock.

A number of other equities analysts also recently weighed in on ZURA. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a report on Wednesday, December 11th. Chardan Capital lowered their price objective on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday. Finally, HC Wainwright reiterated a "neutral" rating and issued a $5.00 target price on shares of Zura Bio in a research note on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $15.00.

Zura Bio Trading Down 6.6 %

Shares of NASDAQ ZURA traded down $0.09 during midday trading on Wednesday, reaching $1.27. The company's stock had a trading volume of 218,258 shares, compared to its average volume of 377,376. The stock has a market capitalization of $82.60 million, a price-to-earnings ratio of -2.39 and a beta of 0.06. Zura Bio has a fifty-two week low of $1.07 and a fifty-two week high of $6.35. The stock has a 50 day simple moving average of $1.46 and a 200-day simple moving average of $2.73.

Remove Ads

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.09. The company had revenue of $0.00 million during the quarter. As a group, equities analysts anticipate that Zura Bio will post -0.65 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZURA. Two Sigma Advisers LP bought a new stake in shares of Zura Bio in the fourth quarter valued at approximately $32,000. Shay Capital LLC acquired a new stake in Zura Bio during the fourth quarter worth about $233,000. ProShare Advisors LLC acquired a new position in shares of Zura Bio in the 4th quarter valued at approximately $35,000. Millennium Management LLC lifted its holdings in shares of Zura Bio by 1,499.0% during the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company's stock worth $1,753,000 after acquiring an additional 657,420 shares during the period. Finally, Forefront Analytics LLC increased its stake in Zura Bio by 74.4% in the fourth quarter. Forefront Analytics LLC now owns 53,734 shares of the company's stock valued at $134,000 after acquiring an additional 22,924 shares during the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.